Severe sirolimus-induced acute hepatitis in a renal transplant recipient.
Sirolimus is currently used as an immunosuppressive agent in kidney transplantation due to its lack of nephrotoxicity and antiproliferative properties. However, a large number of side effects has been described with the use of m-Tor inhibitors. Most are reversible when treatment is withdrawn. Hepatotoxicity is one of these side effects, considered as a benign condition and resulting generally in a transitory and small increase in transaminase levels. We report here, to the best of our knowledge, the first case of severe sirolimus-induced acute hepatitis confirmed by liver biopsy, in a renal transplant recipient. This condition was completely cured in few weeks after sirolimus withdrawal.
Jacques
Jeremie
J
Department of Hepatogastroenterology, CHU Dupuytren, Limoges, France.
Dickson
Zara
Z
Carrier
Paul
P
Essig
Marie
M
Guillaudeau
Angélique
A
Lacour
Celine
C
Bocquentin
Frederique
F
Aldigier
Jean-Claude
JC
Rerolle
Jean-Philippe
JP
D000208:Acute Disease; D001706:Biopsy; D002097:C-Reactive Protein / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism / Q000473:pathology*; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000009:adverse effects* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D002097:C-Reactive Protein; D020123:Sirolimus